Chemical and Toxicological Analyses of Lake Calumet (Cook County, Illinois) Sediments

HWRIC Project 88-048NTIS PB90-16072

Summary of Toxicological Data for Aquatic Organisms of Illinois

The data presented in this report contain Information on toxicity testing performed on organisms that could be found In aquatic habitats in Illinois. To compile this information a thorough list of all aquatic organisms in Illinois was required. This was constructed through literature searches and personal communication with scientists who collect and identify Illinois aquatic specimens. Each species name was used to search a database which contained toxicity information on aquatic organisms. No toxicological Information was found for many Illinois species. For most organisms, all available information retrieved from the database is presented. For species on which extensive toxicological research has been performed, data showing 96 hour LC50 or EC50 values and chronic testing values constitute the bulk of the records. In addition to records detailing toxicity values and experimental conditions, a list of tested chemical compounds and organisms is included. Literature citing observations and identification of aquatic organisms within Illinois was the most valuable resource in compiling a list of Illinois aquatic species. Staff of the Illinois Natural History Survey were helpful in recommending the most useful publications, making available their own field lists, and helping to update taxonomy and nomenclature from older reports. In particular we would like to acknowledge Don Webb, Larry Page, Warren Brigham, Mark Wetzel, Kevin Cummings, and Allison Brigham from the INHS Faunistics section and Michael Henebry from the section of Aquatic Biology. To retrieve toxicity data on the aquatic organisms of Illinois, a Chemical Information System, Inc. database, AQUIRE (Aquatic Information Retrieval System), was employed. AQUIRE contains data extracted from publications dealing with the toxic effects of chemical substances on aquatic organisms. Each Latin species name from the compiled Illinois list was used to search records in the database. If AQUIRE matched a record with the species name, the record was stored. If there were an excessive number of matching records, the search was narrowed by specifying particular regimens and/or effective endpoint types. Ultimately a printout of the records pertaining to each organism was produced. The data contained In this report are duplications of the AQUIRE records obtained for Illinois organisms. The taxonomy, habitat, and Illinois distribution is listed immediately preceding the AQUIRE records compiled for each species. These records have been substantially reduced from their original size and are arranged by chemical compound in alphabetical and/or numerical order.published or submitted for publicationis peer reviewe

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Amendment: Assessment of Ecotoxicological Hazard of Waukegan Harbor Sediment

HWRIC Project no. 87-040

Assessment of the Ecotoxicological Hazard of Sediments in Waukegan Harbor, Illinois

NTIS PB88-18483

A Preliminary Environmental Assessment of the Contamination Associated with Lake Calumet, Cook County, Illinois

NTIS PB88-18482